A recent study has shown that Qingfei Paidu soup, a traditional Chinese medicine (TCM) widely used to treat COVID-19, can help reduce the rate of death among hospitalized patients by half, China Daily reported Monday.
The study, led by researchers from Fuwai Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College, examined more than 8,900 hospitalized COVID-19 cases in Hubei Province, the hardest-hit region during the epidemic, from January to May last year.
Nearly 30 percent of the patients had taken Qingfei Paidu as part of their therapies. Results suggest that the mortality rate for those undergoing the TCM treatment stands at 1.2 percent, while the rate for other patients is 4.8 percent, said the report.
Почему принцы Гарри и Уильям отказались от совместной речи
5-tv.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 5-tv.ru Daily Mail and Mail on Sunday newspapers.
Himalaya Therapeutics Announces Appointment of Howe Li as Chief Medical Officer
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
The
Nursing Education Market report is the best to know the trends and opportunities in industry. The forecast, analysis, evaluations and estimations carried out in this report are all based upon the well established tools and techniques such as SWOT analysis and Porter’s Five Forces analysis. These are the authentic tools used in market analysis on which businesses can trust confidently. Research report brings into focus plentiful of factors such as the general market conditions, trends, inclinations, key players, opportunities, and geographical analysis which all aids to take business towards the growth and success.
Nursing education market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.60% in the above mentioned forecast period. The rising geriatric population and chronic illness across the world has been directly impacting the growth of nursing education market.
Himalaya Therapeutics Announces Appointment of Howe Li as Chief Medical Officer
News provided by
Share this article
Share this article
SAN DIEGO, May 3, 2021 /PRNewswire/ Himalaya Therapeutics ( Himalaya ), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ( CAB ) technology platform, today announced the appointment of Howe Li, M.D., as chief medical officer. Dr. Li is a fantastic addition to our team. He has a depth of understanding of not only the patient, as a medical doctor, but also both global and China clinical trial design and execution said Brian Zhang, Ph.D., CEO of Himalaya. Dr. Li fills an absolutely critical role in our organization as we look to launch our clinical trials in Mainland China. He rounds out the executive management of Himalaya for now,